Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | CCR6 | P51684 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | DDX3X | O00571 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3288477 | 0.87 | MEN1 (0.65) | MEN1KMT2AHPGDHSP90AA1NPSR1 | |
| Hydrochloric Acid SCHEMBL8172216 | 0.86 | MEN1 (0.64) | MEN1KMT2AHPGDHSP90AA1NPSR1 | |
| SCHEMBL7382282 | 0.85 | MEN1 (0.59) | MEN1KMT2AHPGDNPC1HSP90AA1 | |
| SCHEMBL11355645 | 0.84 | POLB (0.55) | NPC1HTTSMN1; SMN2MAPTPOLB | |
| SCHEMBL6160833 | 0.83 | RAB9A (0.64) | MEN1KMT2ANPC1SMN1; SMN2MAPT | |
| Ethane SCHEMBL7845714 | 0.82 | MAPT (0.57) | MEN1KMT2APKMHTTSMN1; SMN2 | |
| SCHEMBL10573661 | 0.81 | MEN1 (0.69) | MEN1KMT2AHPGDNPC1HSP90AA1 | |
| SCHEMBL7529513 | 0.81 | MEN1 (0.52) | MEN1KMT2AHPGDNPC1HSP90AA1 | |
| SCHEMBL11816127 | 0.81 | MEN1 (0.62) | MEN1KMT2AHPGDNPC1HSP90AA1 | |
| SCHEMBL7534057 | 0.80 | MEN1 (0.51) | MEN1KMT2AHPGDNPC1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2057173-B1 | AMIDES AS SPHINGOMYELINE INHIBITORS | NOVARTIS AG (CH) | 2014-02-26 | — | — | EP | disclosed |
| US-8119617-B2 | aSMase inhibitors | NOVARTIS AG (CH) | 2012-02-21 | — | — | US | disclosed |
| US-20100022482-A1 | aSMase inhibitors | NOVARTIS AG (CH) | 2010-01-28 | — | — | US | disclosed |
| EP-2057173-A1 | AMIDES AS SPHINGOMYELINE INHIBITORS | Novartis AG (CH) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008022771-A1 | AMIDES AS SPHINGOMYELINE INHIBITORS | NOVARTIS AG (CH) | 2008-02-28 | — | — | WO | disclosed |
| CN-1202096-C | 2-aminothiazoline derivatives and their use as no-synthase inhibitors | AVENTIS PHARMA SA (FR) | 2005-05-18 | — | — | CN | disclosed |
| US-6699895-B2 | CYCLIZING THE TERT-BUTYL-THIOUREA DERIVATIVE TO FORM THE END PRODUCT | AVENTIS PHARMA S.A. (FR) | 2004-03-02 | — | — | US | disclosed |
| CN-1444572-A | 2-aminothiazoline derivatives and their use as no-synthase inhibitors | AVENTIS PHARMA SA (FR) | 2003-09-24 | — | — | CN | disclosed |
| US-20020198243-A1 | 2-aminothiazoline derivatives and process for preparing the same | CARRY JEAN-CHRISTOPHE (FR) | 2002-12-26 | — | — | US | disclosed |
| US-20020187987-A1 | Use of 2-aminothiazoline derivatives as inhibitors of inducible NO-synthase | CARRY JEAN-CHRISTOPHE (FR) | 2002-12-12 | — | — | US | disclosed |
| US-6451821-B1 | ADMINISTERING TO A PATIENT A THERAPEUTICALLY EFFECTIVE AMOUNT OF 2-AMINOTHIAZOLINE DERIVATIVES FOR TREATING OR PREVENTING DISEASE CONDITIONS ASSOCIATED WITH AN ABNORMAL PRODUCTION OF NITRIC OXIDE(NO) | AVENTIS PHARMA S.A. (FR) | 2002-09-17 | — | — | US | disclosed |
| US-20020022631-A1 | Use of 2-aminothiazoline derivatives as inhibitors of inducible no-synthase | AVENTIS PHARMA S.A. (FR) | 2002-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022482-A1 | aSMase inhibitors | SMPD1, SMPD3, SMPD2 | MEN1 2730/4885KMT2A 1761/4885HPGD 1279/4885 |
| US-20020022631-A1 | Use of 2-aminothiazoline derivatives as inhibitors of inducible no-synthase | NOS2, NOS3, NOS1 | MEN1 4869/4885KMT2A 1692/4885HPGD 109/4885 |
| US-20020198243-A1 | 2-aminothiazoline derivatives and process for preparing the same | NOS3, TH, CBR1 | MEN1 4797/4885KMT2A 1810/4885HPGD 175/4885 |
| US-20020187987-A1 | Use of 2-aminothiazoline derivatives as inhibitors of inducible NO-synthase | NOS2, NOS3, NOS1 | MEN1 4862/4885KMT2A 1856/4885HPGD 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.